Navigation Links
Stimuli-responsive drug delivery system prevents transplant rejection
Date:8/13/2014

Boston, MA Following a tissue graft transplantsuch as that of the face, hand, arm or legit is standard for doctors to immediately give transplant recipients immunosuppressant drugs to prevent their body's immune system from rejecting and attacking the new body part. However, there are toxicities associated with delivering these drugs systemically, as well as side effects since suppressing the immune system can make a patient vulnerable to infection.

A global collaboration including researchers from Brigham and Women's Hospital (BWH); Institute for Stem Cell Biology and Regenerative Medicine in Bangalore, India; and University Hospital of Bern, Switzerland, have developed a way to deliver immunosupressant drugs locally and when prompted, with the use of a biomaterial that self-assembles into a hydrogel (jello-like) material. The novel system is able to deliver targeted, controlled release of medication where and when it is needed.

The study is published online August 13, 2014 in Science Translational Medicine.

"This new approach to delivering immunosuppressant therapy suggests that local delivery of the drug to the grafted tissue has benefits in reducing toxicity, as well as markedly improving therapeutic outcomes, and may lead to a paradigm shift in clinical immunosuppressive therapy in transplant surgery," said Jeff Karp, PhD, Division of Biomedical Engineering, BWH Department of Medicine, co-corresponding study author.

Added Robert Rieben, PhD, associate professor of Transplantation Immunology, Department of Clinical Research, University of Bern, co-corresponding study author: "Continuous release of the drugs irrespective of disease severity is a hallmark of existing drug delivery vehicles and could be a thing of the past. Inflammation-directed drug release offers 'judicious use of locally injected drug' that extends the release for months while eliminating systemic toxicity. "

The researchers developed a hydrogel loaded with the immunosuppressant drug tacrolimus. The hydrogel-drug combo is injected under the skin after transplant surgery. The hydrogel remains inactive until it detects an inflammation/immune response from the transplant site, at which point it delivers the immunosuppressant drug for months locally within the transplanted graft.

In pre-clinical studies conducted by the researchers, a one-time, local injection of the hydrogel-drug combo prevented graft rejection for more than 100 days compared to 35.5 days for recipients receiving only tacrolimus and 11 days for recipients without treatment or only receiving hydrogel.

The innovation may also be applied in medical situations outside of transplant surgery.

"This safe, controlled release platform approach functions for over three months from a single injection, and that has broad implications," said Karp. "Nearly every disease has an inflammatory component. Thus we believe the materials we have developed could be used for localized treatment of multiple inflammatory diseases."

Added Praveen Kumar Vemula, PhD, co-corresponding study author: "This approach should also improve patient compliance, as it obviates the need for daily medications. Also, we plan to expand this prototype for the treatment of numerous diseases such as psoriasis, arthritis and cancer." Vemula, now affiliated with the Institute for Stem Cell Biology and Regenerative Medicine in Bangalore, India, developed the hydrogel with Karp while a postdoc in the Karp laboratory.


'/>"/>

Contact: Marjorie Montemayor-Quellenberg
mmontemayor-quellenberg@partners.org
617-534-6383
Brigham and Women's Hospital
Source:Eurekalert  

Related biology technology :

1. Global Market for RNAi Drug Delivery Technologies to Reach $38.8 Billion in 2018; Aptamer Delivery Segment Surging at 58.2% CAGR
2. Penn researchers successfully alleviate pulmonary inflammation with targeted drug delivery
3. Implantable Drug Delivery Devices Market - Global Industry Analysis, Size, Share, Trends And Forecast, 2012 - 2018
4. Gateway Analytical to Present Latest Research at the Drug Delivery to the Lungs Conference in Edinburg, Scotland
5. WavePharma Unveils Proprietary Chitosan-Based Delivery System for Controlled Release of Key Ingredients in Personal Care Products
6. Enteris BioPharma Forms Scientific Advisory Board to Enhance Leadership in Oral Delivery of Peptide and Small Molecule Drugs
7. MultiCell Technologies Files U.S. Patent Application for Targeted Delivery of MCT-485, a Noncoding miRNA for Cancer Treatment
8. European Injectable Drug Delivery Report 2013: Market Forecasts to 2017
9. Enteris BioPharma and Nordic BioSciences KeyBioScience Enter Strategic Licensing Agreement to Develop Metabolic Peptides Using Enteris Proprietary Oral Drug Delivery and Manufacturing Platform
10. Cardiovascular Drug Delivery - Technologies, Markets and Companies - Updated 2012 Report
11. Enteris BioPharma Initiates Business and Development Activities Targeting Oral Delivery of Peptides and Small Molecule Therapeutics
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Stimuli-responsive drug delivery system prevents transplant rejection
(Date:3/29/2017)... ... March 29, 2017 , ... Cancer diagnostics ... in booth 513 at the Association of Community Cancer Centers (ACCC) 43rd Annual ... , CANCERSCAPE unites key stakeholders from leading national organizations to share insights ...
(Date:3/29/2017)... Research and Markets has announced the addition ... Industry Forecast to 2025" report to their offering. ... The Global Agricultural Chelates ... over the next decade to reach approximately $825.4 million by 2025. ... forecasts for all the given segments on global as well as ...
(Date:3/29/2017)... 29, 2017 /PRNewswire/ - The University of Missouri Research ... business of Sterigenics International, and General Atomics (GA), announce ... to the U.S. Nuclear Regulatory Commission (NRC). This marks ... molybdenum-99 (Mo-99). Once operational, production from this facility will ... for Mo-99, which currently must be imported from outside ...
(Date:3/29/2017)... Research and Markets has announced the addition of ... report to their offering. ... The study scope includes key agricultural ... synthetic biology tools and genome editing tools); synthetic biology-enabled chemicals ... and products are analyzed to determine present and future market ...
Breaking Biology Technology:
(Date:3/23/2017)... The report "Gesture Recognition and Touchless Sensing Market by Technology (Touch-based and Touchless), ... published by MarketsandMarkets, the market is expected to be worth USD 18.98 billion ... Continue Reading ... ...      (Logo: ...
(Date:3/20/2017)... At this year,s CeBIT Chancellor Dr. Angela Merkel ... came to the DERMALOG stand together with the Japanese Prime Minster Shinzo ... At the largest German biometrics company the two government leaders could see ... as well as DERMALOGĀ“s multi-biometrics system.   Continue ... ...
(Date:3/9/2017)... FRANCISCO and MOUNTAIN VIEW, Calif. ... , "Eating Well Made Simple," and 23andMe , ... help guide better food choices.  Zipongo can now provide ... their food preferences, health goals and biometrics, but also ... certain food choices. Zipongo,s personalized food decision ...
Breaking Biology News(10 mins):